Zacks Research Issues Positive Forecast for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research raised their Q3 2025 EPS estimates for BioMarin Pharmaceutical in a research note issued to investors on Monday, February 17th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $0.73 per share for the quarter, up from their previous estimate of $0.72. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's FY2025 earnings at $2.71 EPS, Q2 2026 earnings at $0.86 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.97 EPS and FY2026 earnings at $3.52 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 10.10% and a net margin of 14.96%.

BMRN has been the topic of a number of other reports. Scotiabank increased their price target on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a report on Thursday. Wedbush reissued an "outperform" rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday. Canaccord Genuity Group cut their price target on BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating for the company in a research note on Wednesday, October 30th. Robert W. Baird lowered their price target on BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. cut their price objective on BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating for the company in a research report on Wednesday, October 30th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $93.81.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock traded down $0.48 during mid-day trading on Thursday, hitting $68.25. The company had a trading volume of 2,348,882 shares, compared to its average volume of 1,616,799. The company has a market capitalization of $13.01 billion, a price-to-earnings ratio of 31.02, a P/E/G ratio of 0.58 and a beta of 0.28. BioMarin Pharmaceutical has a 12-month low of $60.63 and a 12-month high of $94.85. The company's fifty day moving average is $64.84 and its 200-day moving average is $71.05. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently made changes to their positions in the stock. Mackenzie Financial Corp grew its holdings in BioMarin Pharmaceutical by 203.4% in the 4th quarter. Mackenzie Financial Corp now owns 220,661 shares of the biotechnology company's stock valued at $14,504,000 after buying an additional 147,927 shares in the last quarter. Forum Financial Management LP purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $298,000. Toronto Dominion Bank increased its position in BioMarin Pharmaceutical by 3.8% during the fourth quarter. Toronto Dominion Bank now owns 24,862 shares of the biotechnology company's stock worth $1,634,000 after purchasing an additional 920 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in BioMarin Pharmaceutical during the fourth quarter worth about $263,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in BioMarin Pharmaceutical by 19.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company's stock valued at $69,351,000 after purchasing an additional 174,634 shares during the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.